Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Authors:
- Roy FleischmannRFRoy Fleischmann
- Ronald F. van VollenhovenRVRonald F. van Vollenhoven
- Josef SmolenJSJosef Smolen
- Paul EmeryPEPaul Emery
- Stefan FlorentinusSFStefan Florentinus
- Suchitrita RathmannSRSuchitrita Rathmann
- Hartmut KupperHKHartmut Kupper
- Arthur KavanaughAKArthur Kavanaugh
- P. TaylorPTP. Taylor
- M. GenoveseMGM. Genovese
- E. C. KeystoneEKE. C. Keystone
- E. DrescherEDE. Drescher
Open Access
- 1 April 2013
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (suppl 1) , i44-i55
Abstract
Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA following inadequate response (IR). Methods: OPTIMA was a 78- week, randomized, controlled trial of ADA + MTX vs PBO + MTX in MTX-naïve early (Results: At week 26, significantly more patients had low disease activity, normal function, and/or no radiographic progression with ADA + MTX vs PBO + MTX (Table 1). Differences in clinical and functional outcomes disappeared following additional treatment, when PBO + MTX-IR (n = 348/460) switched to OL ADA + MTX. Addition of OL ADA slowed radiographic progression, but more patients who received ADA + MTX from baseline had no radiographic progression at week 78 than patients who received initial PBO + MTX. Conclusions: Early RA patients treated with PBO + MTX achieved comparable long-term clinical and functional outcomes on a group level as those who began ADA + MTX, but only when therapy was optimized by the addition of ADA in PBO + MTX-IR. Still, ADA + MTX therapy conferred a radiographic benefit although the difference did not appear to translate to an additional functional benefit. Disclosures: P.E., AbbVie, Merck, Pfizer, UCB, Roche, BMS—Provided Expert Advice, Undertaken Trials, AbbVie—AbbVie sponsored the study, contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. R.F., AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, AstraZeneca, BMS, Janssen, Lilly, Novartis—Research Grants, Consultation Fees. S.F., AbbVie—Employee, Stocks. A.K., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, UCB—Research Grants, Consultation Fees. H.K., AbbVie—Employee, Stocks. S.R., AbbVie—Employee, Stocks. J.S., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, GlaxoSmithKline, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB—Research Grants, Consultation Fees. R.V., AbbVie, BMS, GlaxoSmithKline, Human Genome Sciences, Merck, Pfizer, Roche, UCB Pharma—Consultation Fees, Research Support.Keywords
This publication has 3 references indexed in Scilit:
- Developments in Obesity Genetics in the Era of Genome-Wide Association StudiesLifestyle Genomics, 2011
- Pain reporting at different body sites is explained by a single underlying genetic factorRheumatology, 2010
- Importance of genetic influences on chronic widespread painArthritis & Rheumatism, 2006